Marc Schmalzing und University Person-Info 

( Ich bin Marc Schmalzing)
(1 - 13 von 13
)

New Sandoz biosimilar adalimumab data confirms switching from...

www.myscience.ch
LinkedIn · Facebook · Twitter · WhatsApp Web · Email ... to a biosimilar", adds Dr. Marc Schmalzing, Deputy Head Rheumatology and Immunology at University ...

New Sandoz biosimilar adalimumab data confirms Novartiswww.novartis.com › news › media-releases › new-sa...

www.novartis.com
· Marc Schmalzing, Deputy Head Rheumatology and Immunology at University Hospital Würzburg. In 2018, Hyrimoz® was approved for use and ...
+1